Galapagos - Q3 update: new CAR-T data revealed
*Last night, GLPG provided its Q3 update, most notably announcing 1/ new data from its ongoing Ph1/2 CAR-T studies and 2/ a manufacturing agreement with Boston-based Landmark Bio allowing to submit its IND for CAR-T studies in the US. New CAR-T data 1/ further strengthen the assets' efficacy profiles and 2/ provide additional validation for GLPG's point-of-care manufacturing method. We do want to highlight that data are from a limited number of patients and from a variety of cancer types. Hence it is too early to already draw conclusions on the therapeutic potential of these assets; the road to marketGalapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.